Global Sexual Health Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Feb-2017
No. of pages: 250
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Sexual Health Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Sexual Health Partnering 2010 to 2017 provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Sexual Health partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Sexual Health partnering agreement structure

Sexual Health partnering contract documents

Top Sexual Health deals by value

Most active Sexual Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.

The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Sexual Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Sexual Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Sexual Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Sexual Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Sexual Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Sexual Health partnering deals by specific Sexual Health target announced since 2010. The chapter is organized by specific Sexual Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Sexual Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Sexual Health technologies and products.

Report scope

Global Sexual Health Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Sexual Health trends and structure of deals entered into by leading companies worldwide.

Global Sexual Health Partnering 2010 to 2017 includes:

Trends in Sexual Health dealmaking in the biopharma industry since 2010

Analysis of Sexual Health deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Sexual Health deal contract documents

Comprehensive access to over 3500 Sexual Health deal records

The leading Sexual Health deals by value since 2010

Most active Sexual Health dealmakers since 2010

The report includes deals for the following indications: Bacterial vaginosis, Candida albicans (Thrush), Contraception, Erectile dysfunction, Sexual dysfunction, Sexually transmitted disease (STI), Chlamydia, Genital warts, Gonorrhea, Herpes, Syphilis, Trichomoniasis, plus other sexual health indications.

In Global Sexual Health Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Sexual Health Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 100 sexual health deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Sexual Health Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Sexual Health deal trends since 2010

Access Sexual Health deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Sexual Health partner companies

Comprehensive access to over 750 links to actual Sexual Health deals entered into by the world's biopharma companies

Indepth review of Sexual Health deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Sexual Health opportunities

Uncover companies actively partnering Sexual Health opportunities

Global Sexual Health Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Sexual Health dealmaking
2.1. Introduction
2.2. Sexual Health partnering over the years
2.3. Sexual Health partnering by deal type
2.4. Sexual Health partnering by industry sector
2.5. Sexual Health partnering by stage of development
2.6. Sexual Health partnering by technology type
2.7. Sexual Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Sexual Health partnering
3.1. Introduction
3.2. Disclosed financials terms for Sexual Health partnering
3.3. Sexual Health partnering headline values
3.4. Sexual Health deal upfront payments
3.5. Sexual Health deal milestone payments
3.6. Sexual Health royalty rates

Chapter 4 - Leading Sexual Health deals and dealmakers
4.1. Introduction
4.2. Most active in Sexual Health partnering
4.3. List of most active dealmakers in Sexual Health
4.4. Top Sexual Health deals by value

Chapter 5 - Sexual Health contract document directory
5.1. Introduction
5.2. Sexual Health partnering deals where contract document available

Chapter 6 - Sexual Health dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Sexual Health therapeutic target
Appendices
Appendix 1 - Directory of Sexual Health deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Sexual Health deals by deal type 2010 to 2017
Appendix 3 - Directory of Sexual Health deals by stage of development 2010 to 2017
Appendix 4 - Directory of Sexual Health deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Sexual Health partnering since 2010
Figure 2: Sexual Health partnering by deal type since 2010
Figure 3: Sexual Health partnering by industry sector since 2010
Figure 4: Sexual Health partnering by stage of development since 2010
Figure 5: Sexual Health partnering by technology type since 2010
Figure 6: Sexual Health partnering by indication since 2010
Figure 7: Sexual Health deals with a headline value
Figure 8: Sexual Health deals with upfront payment values
Figure 9: Sexual Health deals with milestone payment
Figure 10: Sexual Health deals with royalty rates
Figure 11: Active Sexual Health dealmaking activity- 2010 to 2017
Figure 12: Top Sexual Health deals by value since 2010
  • Global Varicose Vein Treatment Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 24-Mar-2017        Price: US 3480 Onwards        Pages: 118
    There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Scope of the Report: This report focuses on the Varicose Vein Treatment in Global market, especially in North America, Europe and Asia-Pacific......
  • Liver Cirrhosis - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 96
    Liver Cirrhosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver ......
  • Becker Muscular Dystrophy - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 40
    Becker Muscular Dystrophy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape. Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms in......
  • Duchenne Muscular Dystrophy - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 275
    Duchenne Muscular Dystrophy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It co......
  • Fabry Disease - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 67
    Fabry Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptom......
  • Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 82
    Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms......
  • Bone Marrow Transplant Rejection - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 455
    Bone Marrow Transplant Rejection - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells at......
  • Dyslipidemia - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 280
    Dyslipidemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipop......
  • Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 63
    Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H1 2017, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape. Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood ve......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs